Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trafficking kinesin-binding protein 1 (TRAK1) is an intracellular adaptor protein essential for microtubule-based mitochondrial trafficking, primarily in neurons. TRAK1 physically links mitochondria to kinesin-1 motors via interaction with Miro proteins, enabling efficient anterograde and retrograde mitochondrial transport along neuronal axons. TRAK1 also interacts with dynein/dynactin for bidirectional movement and is crucial for proper mitochondrial distribution, function, and membrane potential. Disruption of TRAK1 function (by mutation or pathogenic variants) leads to impaired mitochondrial dynamics, neurodegeneration, and severe neurodevelopmental diseases such as developmental and epileptic encephalopathy 68 (DEE68)[1][2][3]. TRAK1 additionally regulates endosome-to-lysosome trafficking, including GABA-A receptor trafficking, and is required for recruiting O-GlcNAc transferase (OGT) to mitochondrial surfaces, influencing mitochondrial motility and potentially cellular metabolism[3]. No drugs target TRAK1 directly, but its dysfunction highlights therapeutic potential in neurological and mitochondrial disorders.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trafficking kinesin-binding protein 1 (TRAK1).